• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
In a new study, researchers from the Francis-Crick Institute in the United Kingdom identified key genes for the survival of Toxoplasma gondii in mice by using a CRISPR-based gene screening method. Related research results were recently published in the journal of Nature Communications. This study provides a flexible new approach to extending the use of CRISPR screening, which also allows for the simultaneous testing of hundreds of genes in Toxoplasma in mice, thereby greatly reducing the number of research animals used.
A team of researchers from Canada, the United States, and Sweden found that editing a gene involved in the production of proteins that promote muscle strength can alleviate symptoms in a mouse model of muscular dystrophy. In their paper published in the journal of Nature, the team described their experiments with mice and the new knowledge they learned.
In terms of drug development, currently, the most frequently used gene editing technology is the preparation of animal models.
The vaccine can prevent millions of deaths each year and push certain diseases to the brink of survival. However, it turns out that developing effective vaccines against multiple viruses is extremely challenging, if not impossible.
In a recent study, researchers at the University of California, San Francisco described the first concrete example of how a microbiome can interfere with the intended effects of a drug. They focus on L-dopa, the main treatment for Parkinson's disease, which identifies which of the trillions of bacteria are responsible for degrading drugs and how to prevent this microbial interference.
Recently, researchers from the University of Cambridge's Welkom Foundation's Sanger Institute and Open Targets have used the CRISPR/Cas9 technology to destroy more than 300 cancer types from 30 cancer types. Each gene in a cancer model finds thousands of key genes necessary for cancer to survive. The researchers then developed a new system to prioritize the 600 most promising drug targets for developing treatments. These results accelerate the development of targeted therapies and bring scientists closer to building a Cancer Dependency Map (a detailed manual on precise cancer treatment rules) designed to help more patients receive effective treatment. The relevant research results were published online in the journal of Nature.
Both episode checkpoint inhibitors and adoptive cell therapy are novel immunotherapies that have the potential to treat solid tumors such as HBV-associated hepatocellular carcinoma (HCC), however, they all have their own drawbacks.
CRISPR gene editing technology is a revolutionary approach to treating hereditary diseases. However, this tool has not been used to effectively treat long-term chronic diseases. A research team led by Dr. Dongsheng Duan of the University of Missouri School of Medicine has identified and overcomes the barriers to editing CRISPR genes, which may provide the basis for continuous treatment using this technology.
Recently, the top academic journal Nature has published a major study related to CAR-T treatment, a research team led by Professor Car June, the professionals in cancer Immunotherapy and the pioneer of CAR-T therapy unexpectedly discovered a genetic mutation that could overturn traditional CAR-T treatment and is expected to cure patients with leukemia who are hopelessly treated.
Cancer is a chronic disease in which leads millions of people to die every year from worldwide. According to the World Health Organization (WHO), there are about 18 million people diagnosed with cancer worldwide in 2018, and more than 9 million people will die of cancer. By 2030, the number of newly confirmed cases will exceed 23 million each year. The most common types of cancer include lung cancer, breast cancer and colorectal cancer.
